Brief: Gensight Biologics: positive data safety monitoring board review on PIONEER Phase I/II Clinical Trial of GS030

Gensight Biologics SA

15/09/2021 06:35

Sept 15 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS ANNOUNCES POSITIVE DATA SAFETY
MONITORING
BOARD REVIEW OF PIONEER PHASE I/II CLINICAL TRIAL OF GS030 AS
OPTOGENETIC TREATMENT FOR RETINITIS PIGMENTOSA
    * DSMB finds no safety issue for highest dose of GS030
    * DSMB recommends selecting the highest dose (5e11 vg/eye)
for
extension cohort
    * Recruitment of the extension cohort has been initiated

Source text for Eikon:  ID:nBw7c7pLja 
Further company coverage:  SIGHT.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))